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Original Clinical Report
Vasopressin in Conjunction With Norepinephrine 
in Septic Shock: A Retrospective Cohort Study 
From a Low Middle-Income Country
Hussain Ahmed Raza1; Ainan Arshad,  MB BS, FCPS2; Ahmed Ayaz , MB BS1;  
Mohummad H. R. Raja1; Fatima Gauhar1; Maria Khan1; Bushra Jamil , MBBS, FRCP, FACP2
Objectives: Guidelines recommend use of norepinephrine as the first-
line treatment for fluid-refractory septic shock and if septic shock per-
sists vasopressin may be initiated. Since there are limited data from 
low middle-income countries with high disease burden of sepsis, we 
aimed to compare the outcomes of using vasopressin adjunct to nor-
epinephrine in comparison with norepinephrine alone.
Design: Retrospective cohort study.
Setting: Aga Khan University Hospital, Karachi, Pakistan.
Patients: Six-hundred fifty-three patients diagnosed with septic shock 
from January 2019 to December 2019, with 498 given norepineph-
rine only and 155 given norepinephrine-vasopressin combination.
Interventions: None.
Measurements and Main Results: Primary outcome was in-hospital 
mortality. Secondary outcomes were duration of vasopressor used, 
length of hospital stay, length of ICU stay, and days on ventilatory 
support. After adjustment by multivariable logistic regression, it was 
found that mortality was not significantly associated with the norepi-
nephrine-vasopressin combination (adjusted odds ratio, 0.633 [95% 
CI, 0.370–1.081]). However, Sequential Organ Failure Assessment 
score at admission (1.100 [1.014–1.193]), lactate at admission 
(1.167 [1.109–1.227]), duration of vasopressor used (1.481 [1.316–
1.666]), and level of care (3.025 [1.682–5.441]) were found to be 
independently associated with the adjunct usage of norepinephrine 
and vasopressin.
Conclusions: The use of norepinephrine-vasopressin combination 
has remained debatable in literature. Our study showed that although 
there was no difference in mortality between the two groups, admis-
sion Sequential Organ Failure Assessment scores and admission 
lactate levels were found to be significantly higher in the norepineph-
rine-vasopressin group. Hence, physicians from Pakistan used the 
norepinephrine-vasopressin combination in resistant septic shock 
patients who were sicker to begin with. Furthermore, duration of vaso-
pressor therapy and ICU admission were also significantly higher in 
the combination group. Considering the recent hyperinflation of vaso-
pressors costs and that most healthcare expenditure for patients in 
Pakistan is out-of-pocket, this can consequently lead to unwarranted 
financial burden for patients and their families.
Key Words: mortality; norepinephrine; sepsis; septic shock; shock; 
vasopressin
Sepsis, as per the Third International Consensus Definitions for Sepsis and Septic Shock, is defined as a life-threatening organ dysfunction caused by a dysregulated host response to 
infection (1). Septic shock, a subcategory of sepsis, is when there 
are fundamental metabolic, cellular, and circulatory irregulari-
ties present which are significant enough to considerably increase 
mortality. Millions of people are affected by sepsis and septic 
shock every year, causing the death of at least one in four individu-
als (2, 3). Severe septic shock and sepsis are still critical causes of 
mortality and morbidity in present ICUs (4), and despite signifi-
cant improvement in critical care approach, they are still identified 
as the cause of death in 30–50% of hospitalizations (5). Although 
data from low middle-income countries (LMICs) have historically 
been sparse, outcomes of sepsis have found to be disproportion-
ately affected by location, with Rudd et al recently estimating that 
84.8% of sepsis related deaths in 2017 occurred in LMICs (6).
In the event of progression of sepsis to septic shock, where the 
patient is unable to maintain a mean arterial pressure (MAP) of 
65 mm Hg or greater, despite fluid resuscitation, the use of vaso-
pressors is recommended as per the International Guidelines for 
Management of Sepsis and Septic Shock (7). In case norepineph-
rine fails to raise the MAP adequately, vasopressin may be added to 
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the regimen due to “relative vasopressin deficiency” experienced 
within the first 36 hours of onset of septic shock (8, 9). Concomitant 
vasopressin administration has been seen to improve vascular 
tone, MAP, urine output, and creatinine clearance. Additionally, 
vasopressin acts as a catecholamine sparing agent, by effectively 
reducing the dosage of norepinephrine required. This may pre-
vent the occurrence of some of the unwanted effects associated 
with high-dosage of norepinephrine, including but not limited to 
oxidative stress, myocyte injury, and detrimental exacerbation of 
sepsis-associated immunoparalysis (10).
In spite of this, the clinically utility of vasopressin in improv-
ing outcomes is somewhat unclear, with conflicting data from 
prior literature. Two randomized control trials have demonstrated 
no significant improvement in mortality following concomitant 
norepinephrine and vasopressin administration as compared to 
norepinephrine alone (11, 12). Yet, another study demonstrated 
increase in mortality when using vasopressin in addition with 
norepinephrine that norepinephrine alone (54.4% vs 20.3%; 
p < 0.001) (13). Interestingly, within the Vasopressin in Septic 
Shock Trial (VASST) trial, it was found that vasopressin admin-
istration was beneficial for patients categorized with less severe 
septic shock and significantly reduced mortality when compared 
with only norepinephrine (26.5% vs 35.7%; p = 0.05) (11). Further 
to this, studies have also shown that although concomitant usage 
of vasopressin and norepinephrine may not have a mortality ben-
efit, this regimen enables a target MAP of greater than 65 mm Hg 
to be reached more quickly (14).
Pakistan has a high disease burden of sepsis, with limited data 
and research done in this field. Furthermore, a nationwide registry 
of sepsis does not exist. The need for locally sourced data regard-
ing sepsis outcomes, especially from the context of a resource con-
strained setting of an LMIC, is paramount in allowing physicians 
in such areas to make sound evidence-based decisions. Especially 
since the clinical utility of adjunct vasopressin therapy continues 
to remain controversial and at the discretion of the attending phy-
sician. Further to this, the potential benefit of adding vasopres-
sin to the regimen is especially important to elucidate within the 
context of an LMIC, since the majority of healthcare financing is 
through out-of-pocket expenditure, and as such, adding unneces-
sary drugs without a clear rationale may lead to undue financial 
burden to the patient and their family. Hence, the present study 
aims to assess the difference in outcomes between patients receiv-
ing norepinephrine and vasopressin, compared with norepineph-
rine alone, within the setting of an LMIC.
MATERIALS AND METHODS
Study Design and Data Source
This is a retrospective cohort study in which we assessed adult 
patients (>18 yr) diagnosed with septic shock from January 2019 
till December 2019. This study was conducted at the Aga Khan 
University Hospital, which is a Quaternary Care Referral Center with 
740 beds located in Karachi city. The Institutional Review Board at 
Aga Khan University, Karachi, permitted this study to be conducted.
For the retrospective chart review, two reviewers (authors 
F.G., M.K.) independently reviewed patient medical records to 
determine their eligibility. Figure 1 shows a flow diagram repre-
senting the patient selection process. Records of 1,220 patients 
who received vasopressors from January to December 2019 
were screened in order to identify those patients who had fluid-
refractory septic shock and were administered vasopressin and 
norepinephrine. The cases were defined by the International 
Classification of Disease, 9th Edition, Clinical Modification 
codes for sepsis (995.91), severe sepsis (995.92), or septic shock 
(785.52). This method provides a very specific cohort of sepsis; 
hence, it is a careful estimate of sepsis patients, as stated by mod-
ern literature (15).
A total of 567 studies were excluded by the following exclu-
sion criteria: patients in whom vasopressors/inotropes were used 
for reasons other than septic shock; patients who received vaso-
pressors other than norepinephrine and vasopressin, vasopres-
sors used in operation theaters, pregnant mothers, burn injuries; 
patients who had a goal MAP of greater than or equal to 70 mm 
Hg; postcardiac surgery patients, transferred patients from other 
hospitals; and those patients who were discharged from the hospi-
tal on request or left against medical advice.
Outcomes
The main outcome we aimed to measure was in-hospital mor-
tality. Secondary outcomes were duration of vasopressor used, 
length of hospital stay, length of ICU or special care unit (SCU) 
stay, duration of mechanical ventilation, and duration of ventila-
tor free survival (Table 1). Medical ICUs are closed units, whereas 
SCUs are open units, both of which follow standardized care for 
sepsis management including for fluid therapy and antibiotic 
usage, as per sepsis guideline protocols. We also recorded base-
line patient characteristics and hospitalization factors including 
Sequential Organ Failure Assessment (SOFA) scores and quick 
SOFA (qSOFA) scores (Table 2), as well as source of infection and 
etiology (Table 3).
Statistical Analysis
Data analysis was done using IBM SPSS Statistics for Windows, 
version 23 (IBM Corp., Armonk, NY) and Microsoft Excel 2016 
(v16.0). We compared the patient characteristics and clinical 
outcomes of the group given norepinephrine only with norepi-
nephrine and vasopressin. We performed this comparison using 
the chi-square test and Fisher exact test for categorical variables 
and Wilcoxon rank-sum test or Student t test for the continuous 
variables. Univariate and multivariable logistic regression were 
then performed. Variables with p value less than 0.25 on univari-
ate analysis were included in the multivariable model. Any result 
with a p value of less than or equal to 0.05 was considered to be 
significant.
RESULTS
In the period between January 2019 and December 2019, there 
were 870 patients at the Aga Khan University Hospital who were 
diagnosed with septic shock and received vasopressors. After care-
ful assessment of each file, 653 patients met the inclusion criteria 
and were studied in detail. Out of these 653 patients, the number 
of patients given norepinephrine only was 498 (76.3%), whereas 
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the number of patients given norepinephrine and vasopressin was 
155 (23.7%).
The mean age of the patients was 59.7 ± 16.10, the total num-
ber of males was 376 (57.6%), whereas the total number of females 
was 277 (42.4%). The most common comorbid conditions were 
diabetes (49.0%), hypertension (45.2%), and ischemic heart dis-
ease (24.7%). Upon admission, patients who eventually received 
both norepinephrine and vasopressin had a significantly greater 
SOFA score (p = 0.000), qSOFA score (p = 0.005), and serum lactate 
(p = 0.000). Furthermore, the level of care between the groups also 
significantly varied, with patient requiring adjunct vasopressin 
more likely to be admitted to the ICU in comparison with patients 
requiring just norepinephrine. The overall demographics, patient 
characteristics, and hospitalization factors are presented in Table 2.
Figure 1. Patient selection flow diagram showing the screening process used to obtain records of only those patients diagnosed with septic shock who received 
norepinephrine or norepinephrine and vasopressin combination from January to December 2019. MAP = mean arterial pressure.
TABLE 1. Patient Outcomes
Outcomes
Overall  
(n = 653)  
n (%)/Mean ± sd
Norepinephrine  
Only (n = 498)  
n (%)/Mean ± sd
Norepinephrine and  
Vasopressin (n = 155) 
n (%)/Mean ± sd p
Mortality, n (%) 312 (47.8) 226 (45.4) 86 (55.5) 0.028
Length of hospital stay (d), mean ± sd 8.0 ± 6.20 8.2 ± 6.21 7.4 ± 6.15 0.205
ICU/special care unit length of stay (d), mean ± sd 6.1 ± 4.59 6.2 ± 4.54 5.8 ± 4.76 0.441
Duration on ventilator (d), mean ± sd 5.0 ± 4.08 5.0 ± 3.93 4.8 ± 4.53 0.688
Duration off ventilator (d), mean ± sd 3.0 ± 3.98 3.2 ± 4.18 2.5 ± 3.21 0.071
Duration of vasopressor use (d), mean ± sd 2.4 ± 1.61 2.2 ± 1.44 3.2 ± 1.90 0.000
Boldface values indicate statistically significant (p value ≤0.05) upon analysis.
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The most common source of infection was unspecified (43.6%) 
followed by respiratory tract (24.7%) and urinary (14.5%). The 
majority of patients (58.7%) in septic shock did not have any posi-
tive site-specific or blood cultures. Additionally, there was a sig-
nificant difference in the culture reports between the two groups 
(p = 0.040). Patients who received norepinephrine alone had a 
significantly higher proportion of culture negative reports (60.6% 
vs 52.8%), whereas patients who received both vasopressors had a 
significantly greater proportion of polymicrobial culture reports 
(13.8% vs 8.6%). Detailed microbiological characteristics are pre-
sented in Table 3.
The overall mortality for the patients was 312 (47.8%), with sig-
nificantly increased mortality in the group given both norepineph-
rine and vasopressin (55.5% vs 45.4%) (p = 0.028). Additionally, 
patients given both norepinephrine and vasopressin were on 
vasopressor therapy for a longer period of time (3.2 vs 2.2 d) (p = 
0.000). Hospital outcomes of both groups are reported in Table 1. 
After performing univariate and multivariable logistic regression, 
while adjusting for potential confounders, including age, gender, 
Charlson Comorbidity Index, and other admission variables, 
it revealed that mortality was not significantly associated to the 
norepinephrine-vasopressin group (adjusted odds ratio [aOR], 
0.633 [95% CI, 0.370–1.081]). However, SOFA score at admission 
(aOR, 1.100 [95% CI, 1.014–1.193]), lactate at admission (1.167 
[1.109–1.227]), duration of vasopressor use (1.481 [1.316–1.666]), 
and level of care (3.025 [1.682–5.441]) were found to be indepen-
dently associated with the adjunct usage of norepinephrine and 
vasopressin. These findings are presented in Table 4.
DISCUSSION
There is a lack of high-quality data on septic shock and vasopres-
sors from LMICs, and to our knowledge, this is the first study in 
a resource-constrained setting of an LMIC that has compared the 
use of vasopressin in adjunct to norepinephrine versus the use 
of norepinephrine alone for the treatment of septic shock. Our 
study demonstrated that initially it appeared patients receiving 
both norepinephrine and vasopressin had statistically significant 
higher rates of mortality than those who received norepineph-
rine alone. However, once confounding factors were adjusted 
for, there was no longer a significant difference between mortal-
ity in the two groups, indicating that the mortality in the dual 
therapy group was likely due to the higher admission lactate and 
admission SOFA scores, rather than the vasopressor combination 
itself. This result is largely in line with results from the VASST, 
TABLE 2. Patients Characteristics and Hospitalization Factors
Variables
Overall  
(n = 653) 
Norepinephrine 
Only (n = 498) 
Norepinephrine  
and Vasopressin 
(n = 155) p
Mean age (yr), mean ± sd 59.7 ± 16.10 60.9 ± 15.86 55.9 ± 16.33 0.001
Gender, n (%)
 Male 376 (57.6) 284 (57.0) 92 (59.4) 0.609
 Female 277 (42.4) 214 (43.0) 63 (40.6)  
Comorbid conditions, n (%)
 Diabetes 320 (49.0) 247 (49.6) 73 (47.1) 0.586
 Hypertension 295 (45.2) 224 (45.0) 71 (45.8) 0.857
 Ischemic heart disease 161 (24.7) 125 (25.1) 36 (23.2) 0.636
 Chronic kidney disease 153 (23.4) 112 (22.5) 41 (26.5) 0.309
 Malignancy 69 (10.6) 51 (10.2) 18 (11.6) 0.628
 Charlson Comorbidity Index, mean ± sd 3.9 ± 2.56 4.0 ± 2.56 3.7 ± 2.56 0.246
Hospitalization factors, mean ± sd
 SOFA score at admission 5.3 ± 3.35 5.0 ± 3.21 6.3 ± 3.60 0.000
 Quick SOFA score at admission 1.5 ± 1.03 1.5 ± 1.04 1.7 ± 0.97 0.005
 Lactate at admission (mmol/L) 4.3 ± 3.80 3.7 ± 3.28 6.1 ± 4.69 0.000
 Serum creatinine at admission (mg/dL) 3.0 ± 2.86 3.0 ± 3.07 3.0 ± 2.08 0.775
 Hemoglobin at admission (g/dL) 10.7 ± 2.52 10.6 ± 2.41 10.9 ± 2.85 0.350
Level of care, n (%)
 Patients in ICU care 497 (76.1) 359 (72.1) 138 (89.0) 0.000
 Patient in special care unit care 156 (23.9) 139 (27.9) 17 (11.0)  
SOFA = Sequential Organ Failure Assessment. 
Boldface values indicate statistically significant (p value ≤0.05) upon analysis.
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a multicenter, double-blind, randomized control trial published 
in 2008, which reported that the administration of vasopressin at 
0.03 U/min 12 hours after the initiation of norepinephrine therapy 
did not significantly alter the 28-day and 90-day mortality rates, 
when compared with norepinephrine alone (11). The results of 
the vasopressin versus norepinephrine as Initial Therapy in Septic 
Shock (VANISH) trial conducted in 2016 also stated there was no 
difference in mortality between patients given norepinephrine 
versus vasopressin (12). In fact, in a recent meta-analysis which 
assessed mortality rates in 17 clinical trials which were comparing 
vasopressin in combination with catecholamine vasopressors with 
catecholamines alone, it was concluded that although mortality 
appeared to be lower in the dual therapy group, upon sensitivity 
analysis it was no longer significant (16). Yet interestingly, in the 
VASST trial, it was noted that vasopressin administration signifi-
cantly improved 28-day and 90-day survival rates in the subset of 
patients with less severe septic shock (patients who were receiving 
norepinephrine at an infusion rate of < 15 μg/min) (11). This find-
ing is somewhat contradictory to current guidelines and practices 
which suggest that adjunct use of vasopressin, in addition to nor-
epinephrine, is only recommended when the patient is unable to 
maintain a MAP above 65 mm Hg with the use of norepinephrine 
alone, implying that vasopressin is essentially reserved as a sec-
ond-line drug to be used in patients with severe septic shock (7). 
The results of our study reflect the practice of current guidelines, 
as patients receiving both drugs were clearly sicker from the onset, 
as they had significantly higher admission lactate levels and higher 
admission SOFA scores, which are well-established prognostic 
indicators in septic shock management.
To date, there have been few studies that have shown negative 
clinical outcomes associated with the use of vasopressin along with 
norepinephrine. In 2007, Micek et al (13) demonstrated increased 
28-day mortality with the adjunct use of vasopressin with nor-
epinephrine, in conditions of refractory septic shock (54.4% in 
vasopressin group vs. 20.3% in norepinephrine group, p < 0.001), 
concluding that the negative effects caused by the mechanism of 
action of vasopressin led to the increased mortality. In a propen-
sity matched retrospective cohort study, Russell et al (17) found 
that in the same hospital where the VASST trial was conducted, a 
similar condition was found in the pre-VASST trial cohort study 
conducted at St. Paul’s Hospital (SPH1) (28-d mortality: 60.8% in 
vasopressin group vs 46.2% in norepinephrine group; p = 0.009). 
However, in the post-VASST trial cohort study conducted at St. 
Paul’s Hospital (SPH2), the in-hospital mortality between the two 
groups became statistically insignificant (28-d mortality: 31.2% in 
vasopressin group vs 26.9% in norepinephrine group; p = 0.518). 
A key factor to be noted is that the day 1 dose of vasopressin 
administered by physicians between the two periods was signifi-
cantly different (0.036 U/min (SPH1) vs 0.032 U/min (SPH2); p = 
0.001). The decrease in dosage associated with post-VASST period 
TABLE 3. Source of Infection and Etiology
Characteristics
Overall  
(n = 653), 
 n (%)
Norepinephrine  
Only (n = 498),  
n (%)
Norepinephrine and 
Vasopressin (n = 155), 
n (%) p
Source of infection    
 Respiratory 161 (24.7) 117 (23.5) 44 (28.4) 0.702
 Urinary 95 (14.5) 78 (15.7) 17 (11.0)
 Central Line Associated 
Blood Stream Infection
14 (2.1) 11 (2.2) 3 (1.9)
 Cardiac 7 (1.1) 5 (1.0) 2 (1.3)
 CNS 9 (1.4) 7 (1.4) 2 (1.3)
 Skin/soft tissue 40 (6.1) 32 (6.4) 8 (5.2)
 Gastrointestinal 42 (6.4) 29 (5.8) 13 (8.4)
 Unspecified 285 (43.6) 219 (44.0) 66 (42.6)
Culture Etiology
Overall  
(n = 496) 
Norepinephrine  
Only (n = 373) 
Norepinephrine  
and Vasopressin  
(n = 123) p
 Culture results    
  Culture negative 291 (58.7) 226 (60.6) 65 (52.8)  0.040 
  Polymicrobial 49 (9.9) 32 (8.6) 17 (13.8)
  Gram positive 34 (6.9) 22 (5.9) 12 (9.8)
  Gram negative 97 (19.6) 78 (20.9) 19 (15.4)
  Fungi 25 (5.0) 15 (4.0) 10 (8.1)
Boldface value indicates statistically significant (p value ≤0.05) upon analysis.
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appears to have reduced the mortality in the vasopressin group. In 
conjunction with this, literature has reported that higher doses of 
vasopressin are associated with several adverse outcomes, includ-
ing ischemic complications of the heart, gut, and renal systems 
(18).
The serum lactate level is a key biomarker to predict mortal-
ity and prognostic outcome in patients with septic shock. Current 
guidelines suggest initiating and monitoring resuscitation therapy 
in such a manner so as to normalize raised lactate levels, with 
elevated lactate levels being an indicator of tissue hypoperfusion 
(7). Lower lactate levels with greater lactate clearance have consis-
tently been associated with improved outcomes and lower mortal-
ity (19–21). In fact, a recent study by Liu et al (22) found lactate to 
be an independent predictor for mortality in septic patients. This 
has been substantiated by our study’s results, which demonstrated 
that higher mortality was not due to the vasopressor combination 
itself but rather due to the higher admission lactate level which 
was independently associated to the norepinephrine-vasopressin 
group. This once again demonstrates that physicians continue to 
reserve the use of dual therapy in patients who are significantly 
sicker. However, a post hoc analysis of the VASST trial found 
that vasopressin administration had a significant mortality ben-
efit for lower serum lactate concentration (< 2 mmol/L) rather 
than higher lactate levels above 2 mmol/L (23). These findings 
were corroborated by Sacha et al (24) with a reduced lactate lev-
els independently associated with a greater chance of an adequate 
hemodynamic response to vasopressin and norepinephrine ther-
apy. To potentially explain this phenomenon, Severson et al (25) 
showed that administration of vasopressin was associated with 
rising serum lactate levels during therapy. As such adjunct vaso-
pressin therapy may have the potential to elevate the serum lac-
tate levels further despite our findings suggesting that vasopressin 
administration in conjunct to norepinephrine was not associated 
to increased mortality. These studies demonstrate findings that 
are largely in contradiction to the currently accepted practices, 
where vasopressin is reserved for substantially sicker patients. 
Although both groups in the present study had mean lactate levels 
at admission well above the cut off value of 2 mmol/L which was 
TABLE 4. Univariate and Multivariable Logistic Regression
Variables
Norepinephrine and Vasopressin
Crude OR (95% CI) p Adjusted OR (95% CI)a p 
Age 0.981 (0.971–0.992) 0.001 0.985 (0.971–0.999) 0.043
Gender     
 Male 1.100 (0.763–1.587) 0.609   
 Female Reference   
Diabetes 0.905 (0.631–1.298) 0.586   
Hypertension 1.034 (0.720–1.485) 0.857   
Ischemic heart disease 0.903 (0.591–1.380) 0.636   
Chronic kidney disease 1.240 (0.819–1.876) 0.310   
Malignancy 1.152 (0.651–2.037) 0.628   
Charlson Comorbidity Index 0.958 (0.892–1.030) 0.246 0.977 (0.890–1.072) 0.618
Hemoglobin at admission (g/dL) 1.038 (0.967–1.114) 0.307   
Serum creatinine at admission (mg/dL) 0.991 (0.929–1.056) 0.774   
SOFA score at admission 1.125 (1.066–1.188) < 0.001 1.100 (1.014–1.193) 0.022
Quick SOFA score at admission 1.278 (1.070–1.525) 0.007 1.134 (0.868–1.483) 0.357
Lactate at admission (mmol/L) 1.159 (1.108–1.212) < 0.001 1.167 (1.109–1.227) < 0.001
Duration on ventilator (s) 0.991 (0.947–1.036) 0.688   
Duration of vasopressor use (s) 1.403 (1.259–1.564) < 0.001 1.481 (1.316–1.666) < 0.001
Level of care     
 Patients in ICU care 3.143 (1.831–5.396) < 0.001 3.025 (1.682–5.441) < 0.001
 Patients in Special Care Unit care Reference    
Mortality 1.500 (1.044–2.156) 0.028 0.633 (0.370–1.081) 0.094
OR = odds ratio, SOFA = Sequential Organ Failure Assessment. 
aAdjusted for variables with p < 0.25 on univariate analysis. 
Boldface values indicate statistically significant (p value ≤0.05) upon analysis.
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used in these previous studies, our results support the notion that 
increased lactate levels are associated to vasopressin-norepineph-
rine usage. The question remains, however as to what lactate level 
is appropriate to begin adjunct vasopressin therapy, for which fur-
ther large-scale studies are needed.
Additionally, in our study, a higher SOFA score at admission 
was independently associated to patients in the norepinephrine-
vasopressin group compared with the norepinephrine group. The 
SOFA score, originally designed to predict ICU mortality, mea-
sures organ dysfunction in six organ systems and is a key predictor 
of mortality in patients with septic shock. Jones et al (26) showed 
that SOFA scores can be used to predict mortality with fairly good 
accuracy in patients with severe sepsis at the time of presentation 
in the emergency department. This was reflected in our study 
since the mortality in the combination group was not significant 
upon adjustment, indicating that the higher SOFA scores of the 
combination group patients caused the patients to be more critical 
to begin with. However, a study conducted by Hammond et al (14) 
did show a contrasting finding that there was no significant differ-
ence in median SOFA scores between norepinephrine alone ver-
sus vasopressin and norepinephrine. Nonetheless, SOFA score has 
been shown to have strong discriminative power, similar to lac-
tate, for predicting 30-day mortality as shown by a recent study of 
sepsis patients (22). This once again reflects in physician attitudes 
practicing within an LMIC, suggesting that they are more likely to 
start dual therapy in case of higher SOFA scores and continue to 
use it along with lactate as an important prognostic indicator in 
predicting mortality in septic patients.
Following logistic regression, our study also found that longer 
duration of vasopressor therapy and ICU admission were inde-
pendently associated to the norepinephrine-vasopressin combina-
tion group. This is most likely a manifestation of severity of sepsis 
and use of combination therapy for sicker patients who were not 
responding to norepinephrine alone. Patients in the combination 
group were undoubtedly found to be more critical upon admission, 
with higher lactate and SOFA scores, leading to their protracted 
course of illness and hence needing longer duration of therapy 
and more ICU admission. Although appropriate recognition and 
management of septic shock is vital to prevent unwarranted mor-
tality, economic restraints and costs for sepsis treatment cannot be 
ignored especially in LMICs such as Pakistan. Globally, sepsis is 
widely regarded as one of the most expensive conditions to treat. 
Although data for LMICs have historically been sparse, it would 
be unfair to underestimate that the impact of healthcare costs in 
LMICs. Within a high-income country like the United States, the 
treatment and subsequent management of sepsis is estimated to 
have an annual cost of approximately $20 billion (27). Sepsis treat-
ment costs at a LMIC like Indonesia, varied between $1,011 and 
$1,406 per patient, with the national burden estimated to be $130 
million per 100,000 sepsis patients (28). This is particularly trou-
bling since Pakistan, which has a similar population to Indonesia, 
has an entire healthcare budget of approximately only $150 mil-
lion for the fiscal year 2020–2021 (29). To add to this financial 
crisis, in the recent years, hyperinflation of vasopressor drugs has 
drastically occurred, with vasopressin cost in particular increasing 
by 60-fold in 2017 than it did in 2015 as shown by a study (30). 
Although healthcare costs in the United States are covered mostly 
by medical insurance, in majority of LMICs like Pakistan, very 
minimal percentage of the population has access to any form of 
health insurance that covers medicine costs. Thus, it is evident 
that most healthcare financing in Pakistan is out-of-pocket, with 
70% of healthcare costs being covered by this method (31). High 
costs severely restrict access to ICU care in LMICs, especially for 
the majority of the population in Pakistan who are socioeconomi-
cally deprived and uninsured. In fact, many patients in Pakistan 
who cannot afford healthcare costs, especially in private hospitals, 
often leave the hospital against medical advice. The longer dura-
tion of vasopressor treatment and ICU admission, along with the 
mammoth out-of-pocket healthcare costs for treatment, will cause 
patients and their families in LMICs like Pakistan to experience 
significant unwarranted financial burden. This may further limit 
access to vital healthcare and treatment in Pakistan and conse-
quently leads to unfortunate outcomes for septic shock patients, 
due to the lack of affordability. Therefore, further large-scale stud-
ies, particularly in LMICs, are required which advocates for the 
clinical benefit of using vasopressin and norepinephrine, so that 
both patients and physicians alike are assured that the high costs 
for vasopressor treatment are justified.
One of the limitations of this study is that being a retrospec-
tive study, the results may have been influenced by unmeasured 
residual confounding factors. Furthermore, the present study is 
a single-center study, inevitably leading to a smaller sample size 
as compared to multicenter studies. In the given study, the SOFA, 
qSOFA, and serum lactate levels were recorded upon admission 
and were not charted during the hospital admission. To gain a bet-
ter understanding, further prospective studies are required where 
these variables are monitored in conjunction with administration 
of vasopressors. Further to this, due to the retrospective nature of 
the study, the initiation timings and dosage of vasopressors could 
not be accurately determined from our medical records, and 
hence these factors were not included in the study. Prior literature 
has shown that the timing of the dose of vasopressin may also be 
critical in eliciting a positive response. In fact, Lauzier et al (32) 
recently demonstrated that vasopressin administration was not 
able to raise and maintain the MAP above 70 mm Hg for most 
patients, in the early phases of hyperdynamic septic shock. The 
VANISH trial also found that higher doses of vasopressin (up to 
0.06 U/min), administered within 6 hours of the patient entering 
septic shock had no effect on mortality (12). Therefore, further 
large-scale studies specifically deducing whether the timing of 
vasopressor administration significantly affects outcomes within 
an LMIC are warranted. Finally, another limitation lies in iden-
tifying septic shock by using MAP. Even though MAP is used 
routinely in clinical practice, other clinical variables are also used 
for the diagnosis of shock. Furthermore, a MAP of below 65 mm 
Hg does not always mean under perfusion of organs and cellular 
injury (33). Nevertheless, ICUs continue to use MAP as an indica-
tor of septic shock, and since it is easily accessible, it remains as 
an ideal marker for future studies similar to ours. Despite these 
limitations, this study presents important results that are of clini-
cal relevance, especially considering that this is the first study of 
its kind conducted in a LMIC, which has significantly different 
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socioeconomic demographic conditions. Furthermore, this article 
advocates that the vasopressin should be used with caution, espe-
cially considering the fact that there is reported potential overuse 
of vasopressin among physicians in the United States (34).
CONCLUSIONS
The benefit of the use of Vasopressin in adjunct to Norepinephrine 
has remained debatable in scientific literature, with a lack of data 
from LMICs. Our study showed that although there was no dif-
ference in mortality between the two groups, admission SOFA 
scores and admission lactate levels were found to be significantly 
higher in the norepinephrine-vasopressin combination group. 
Hence, physicians from Pakistan used the combination ther-
apy in resistant septic shock patients who were sicker to begin 
with. Furthermore, duration of vasopressor therapy and ICU 
admission was also significantly higher in the norepinephrine-
vasopressin group. Considering the recent hyperinflation of vaso-
pressors costs and that most healthcare expenditure for patients 
in Pakistan is out-of-pocket, this can consequently lead to unwar-
ranted financial burden for patients and their families. Therefore, 
future studies, especially from LMICs, are needed to justify the 
usage of vasopressin and norepinephrine for the treatment of sep-
tic shock.
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